SCHEMBL3436682

SCHEMBL3436682

Cc1nc(-c2cccs2)sc1CO

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.58
ALDH1A1 P00352 5/20 0.58
GAA P10253 2/20 0.56
RAB9A P51151 4/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
GLA P06280 1/20 0.49
NPC1 O15118 1/20 0.45
PPARG P37231 1/20 0.43
NCOA2 Q15596 1/20 0.43
NCOA1 Q15788 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
DPP4 P27487 1/20 0.42
FBP1 P09467 1/20 0.41
MAPT P10636 4/20 0.41
MEN1 O00255 1/20 0.41
HPGD P15428 1/20 0.41
CASP3 P42574 1/20 0.41
KMT2A Q03164 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL289837 0.91 DPP4 (0.53) KDM4EALDH1A1GAARAB9AL3MBTL1
SCHEMBL27567650 0.88 KDM4E (0.55) KDM4EALDH1A1GAARAB9AL3MBTL1
SCHEMBL288142 0.80 KDM4E (0.54) KDM4EALDH1A1GAARAB9AL3MBTL1
SCHEMBL27503350 0.80 KDM4E (0.50) KDM4EALDH1A1GAARAB9AL3MBTL1
SCHEMBL3828017 0.78 ALDH1A1 (0.37) KDM4EALDH1A1GAARAB9ANPC1
SCHEMBL279138 0.78 KDM4E (0.49) KDM4EALDH1A1GAARAB9AL3MBTL1
SCHEMBL10091957 0.78 KDM4E (0.61) KDM4EALDH1A1GAARAB9AL3MBTL1
SCHEMBL3077683 0.75 SMN1; SMN2 (0.56) KDM4EALDH1A1GAARAB9AL3MBTL1
SCHEMBL27016991 0.75 KDM4E (0.58) KDM4EALDH1A1GAARAB9AL3MBTL1
SCHEMBL290132 0.74 KDM4E (1.00) KDM4EALDH1A1GAARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594555-B1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA PHARM CO LTD (JP) 2018-03-07 EP disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 US disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 US disclosed
EP-2594555-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA Pharmaceutical Co., Ltd. (JP) 2013-05-22 EP disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 US disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 US disclosed
WO-2012002527-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR あすか製薬株式会社 (JP) 2012-01-05 WO disclosed
CN-101007790-A Oxamic acid derivative, and its preparation method and medicinal uses BEIJING MOLIKE SCIENCE AND TEC (CN) 2007-08-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR CDKN1A, SKP2, CCNI KDM4E 1069/4885ALDH1A1 1594/4885GAA 3220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.